A New Once-Daily Pill for Crohn's Disease Launched

 

The FDA has authorised RINVOQ® (upadacitinib) for the treatment of individuals with moderately to highly active Crohn's disease who have not responded well to or are intolerant of one or more TNF blockers, according to a statement from AbbVie. RINVOQ has already received seven FDA approvals in the fields of gastroenterology, dermatology, and rheumatology, where it is now approved for both Crohn's disease and ulcerative colitis.